Cell Source, Inc. · OTC:CLCS
Cell Source — Investor Presentation (May 2015)
21 slides from Cell Source's investor presentation, May 28, 2015
Slide 1: Cell Source Breakthrough Immunotherapy Technologies Corporate Overview
Cell Source Breakthrough Immunotherapy Technologies C orporate Overview CLCS (OTCQB)
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties . The actual future results of Cell Source could differ significantly from those statements . Factors that could cause actual res
Slide 3: Company Overview
Ticker: CLCS Cell Source is an immunotherapy and regenerative cell therapy company. Cell Source’s primary breakthrough technologies* improve the regulation of immune tolerance, in order to: • Facilitate safer and more accessible (thus more successful) bone marrow and major organ transplantation • Ef
Slide 4: Unmet needs in transplantation and blood cancers
• Organ and bone marrow transplantation ( BMT ) - 100,000 Americans, 1.5 million Chinese on waiting lists - Intensive immune suppression treatments (radiation and chemotherapy) lead to up to 50% transplant related mortality rates in allogeneic* BMT - Organ transplant recipients take anti - rejection
Slide 5: Cell Source Solution – Veto Cells
• The immune system dispatches T - cell clones that exclusively attack a specific “threat” • Cell Source’s Veto cells disable the attack of the immune system on the bone marrow transplantation (BMT) only , without other side effects • The Veto cells act as “decoys” that attract, then kill, the T - c
Slide 6: Pre-Clinical Results: Safer BMT
Attacking cell TCM cell * T Central Memory are specially treated human cells Live video shows TCM * counterattacking rejecting T - cell clones • Results published in peer - reviewed scientific journal Blood in 02, 2013 • Mice received mismatched BMT with reduced levels of immune suppression treated
Slide 7: Veto Cells Eradicate Lymphoma in Mice
• Veto cells proactively attack and kill lymphoma (blood cancer) cells in mice: • Veto cells in mice traveled throughout the body, identifying and attacking only the malignant lymphoma cells • Veto cells live on to kill more lymphoma cells, and the body remains cancer - free for prolonged periods of
Slide 8: Results: Killing Lymphoma in Mice
Cancer cell TCM cell Live video shows TCM cell tracking, attacking and killing a lymphoma cell Ticker: CLCS • Results published in peer - reviewed scientific journal Blood in 02, 2013 • Mice with lymphoma treated with Cell Source Veto cells • All mice in the untreated group died • Veto cell treated
Slide 9: Megadose + Drug Combination
• Professor Yair Reisner, former Chairman of the Department of Immunology of Israel’s Weizmann Institute of Science pioneered “mismatched” BMT (partial vs. full donor/recipient match) with his patented “Megadose” cell therapy treatment • Cell Source’s “drug combination” treatment* facilitates matche
Slide 10: Organ Regeneration Platform
• Revolutionary, new means of growing or repairing major human organs using proprietary technology. • Porcine (pig) embryonic tissue or cells can be harvested specifically targeting individual organs (e.g., pancreas, lung). Pig embryo “pre pancreas” that is harvested and transplanted into the host’s
Slide 11: Grew Functioning Pancreas In Mice
1 millimeter “pre - pancreas” harvested from pig embryo… … grows into 10 millimeter functional pancreas beside mouse’s diabetic pancreas * Producing insulin that effectively reversed Type 1 diabetes ; similar results achieved in monkeys as well Grew Functioning Pancreas* In Mice Ticker: CLCS
Slide 12: Platforms, method of action and target indications
Platform Method of action Target indications / applications Veto Cells • Special blood cells facilitate transplants – attract then counterattack and kill immune rejecting T - cells • Directly attacking and killing tumor (blood cancer) cells • Matched and mismatched organ and bone marrow transplants
Slide 13: Intellectual Property
Invention Patents granted/allowed Patents pending approval Anti - rejection Veto Cell • 2 patent families • 5 patents • 2 patent families • 20 patent applications Anti - lymphoma/leukemia Veto Cell • Original Veto Cell patent acts as priority • 1 patent family • 11 patent applications * Patent famil
Slide 14: Timelines Going Forward
Q2 H2 H1 H2 H1 H2 Megadose Drug Combo. Anti - rejection Veto Cell Anti - lymphoma Veto Cell 2015 2016 2017 Organ repair platform Preclinical Awaiting approval Sponsored study Spontaneous study Preliminary data Key next steps: 1. Initial Megadose Drug Combo. human data 2. Submission of Veto cell prot
Slide 15: Comparable companies and valuations
• Typical synthetic drug approval cycle is 6 to 8 years from commencing Phase I • Lifesaving treatments with combined Phase I/II have potential to reach market within 3 - 5 years Comparable Company Ticker Market Cap Phase & Indication CURRENT VALUATIONS Kite Pharma KITE $2.3 Billion Immunotherapy Ph
Slide 16: Technology comparison with CAR-T and BiTE
• In the best case, Cell Source technology could outmode both CAR - T and BiTE for the most common forms for Lymphoma and Leukemia • Otherwise, Cell Source technology could likely become a key enabler for CAR - T in overcoming rejection and possibly even neurotoxicity Technology Companies * Challeng
Slide 17: Weizmann Institute of Science and Yeda
• Israel’s leading academic research institution - Over 1000 professors and scientists, all students MSc and PhD only - Most US patents (top university, top 5 overall along with IBM, Intel and Teva ) • Among top institutions in the world - “Best Place in Academia” ranked No.1 among international aca
Slide 18: Management and Board
• Yoram Drucker, Chairman an Israeli entrepreneur and executive at two successful cell therapy technology firms. He cofounded two NASDAQ listed cell stem therapy companies Brainstorm (currently valued at ~$60M) and Pluristem (~$200M) • Dr. Dennis M. Brown, Director Former Chairman of Mountain View a
Slide 19: Overview Timeline 2015
• Clinical - First human data on Megadose Drug Combination - Submission of human Veto Cell protocols for approval • Financial - $5+ million bridge funding round currently underway - Planned $20+ million secondary financing and stock uplist • Preclinical and academic - Publication of proof - of - con
Slide 20: Investment Highlights
• State - of - the - art patent and patent - pending technologies in the field of Immunotherapies and Transplantation from one of world’s top scientific institutions • A publically traded and undervalued immunotherapy company, with the potential to meet or surpass clinical results of immunotherapy m
Slide 21: Follow Up Information
Follow Up Information Itamar Shimrat CEO Cell Source Ticker: CLCS info@cell - source.com © Copyright Cell Source, Inc. – All Rights Reserved.